tetano
Editor, Senior Moderator
Clin Case Rep
. 2022 Apr 15;10(4):e05744.
doi: 10.1002/ccr3.5744. eCollection 2022 Apr.
Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID-19 vaccination: A case report
Shakiba Hassanzadeh[SUP] 1 [/SUP], Somayeh Sadeghi[SUP] 2 [/SUP], Ahmad Mirdamadi[SUP] 3 [/SUP], Alireza Nematollahi[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease-19 (COVID-19) vaccines are massively administered globally and some adverse events, such as myocarditis, are being reported. Most of the reported cases of post-vaccination myocarditis have occurred following mRNA vaccinations. However, there have also been recent reports of myocarditis following adenovirus vector vaccinations. We present a case of a 32-year-old female patient who developed myocarditis following the administration of the first dose of the AstraZeneca vaccine. The patient developed inappropriate exertional tachycardia and exertional dyspnea from Day 3 and was diagnosed with myocarditis by subsequent echocardiography about 3 months later. We are unable to confirm a direct association between myocarditis and AstraZeneca vaccination. However, we would like to increase awareness regarding the possibility of developing myocarditis following AstraZeneca vaccination.
Keywords: AstraZeneca‐associated myocarditis; COVID‐19 vaccination‐associated myocarditis; mRNA COVID‐19 vaccines; myocarditis; viral vector vaccines.
. 2022 Apr 15;10(4):e05744.
doi: 10.1002/ccr3.5744. eCollection 2022 Apr.
Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID-19 vaccination: A case report
Shakiba Hassanzadeh[SUP] 1 [/SUP], Somayeh Sadeghi[SUP] 2 [/SUP], Ahmad Mirdamadi[SUP] 3 [/SUP], Alireza Nematollahi[SUP] 4 [/SUP]
Affiliations
- PMID: 35441011
- PMCID: PMC9011044
- DOI: 10.1002/ccr3.5744
Abstract
Coronavirus disease-19 (COVID-19) vaccines are massively administered globally and some adverse events, such as myocarditis, are being reported. Most of the reported cases of post-vaccination myocarditis have occurred following mRNA vaccinations. However, there have also been recent reports of myocarditis following adenovirus vector vaccinations. We present a case of a 32-year-old female patient who developed myocarditis following the administration of the first dose of the AstraZeneca vaccine. The patient developed inappropriate exertional tachycardia and exertional dyspnea from Day 3 and was diagnosed with myocarditis by subsequent echocardiography about 3 months later. We are unable to confirm a direct association between myocarditis and AstraZeneca vaccination. However, we would like to increase awareness regarding the possibility of developing myocarditis following AstraZeneca vaccination.
Keywords: AstraZeneca‐associated myocarditis; COVID‐19 vaccination‐associated myocarditis; mRNA COVID‐19 vaccines; myocarditis; viral vector vaccines.